Contingent Value Rights - Year 1 payment obligation
Company: Core Scientific
The claim, verbatim
CVR holders receive at first testing date cash equal to pro rata share of lesser of $43,333,333 or difference between $260 million and fair market value of Corresponding New Common Stock
Source (primary)
Core Scientific 8-K/A filed 2024-01-25 (SEC EDGAR, sec_filing)
View cached copy (2026-08-31)Live source ↗
Quote: “at the first testing date, cash equal to such Payee's pro rata share (the " Year 1 Contingent Payment Obligation ") of the lesser of (a) $43,333,333.33 and (b) the difference between (1) $260,000,000 and (2) the fair market value of the Corresponding New Common Stock”
How we checked this
This claim has not yet been checked assertion-by-assertion against its source. It carries a cited source and quote, but the deeper check has not run. When it does, the result appears here whatever it says.
Additional evidence
confirms Core Scientific 8-K/A filed 2024-01-25
Quote: “at the first testing date, cash equal to such Payee's pro rata share (the " Year 1 Contingent Payment Obligation ") of the lesser of (a) $43,333,333.33 and (b) the difference between (1) $260,000,000 and (2) the fair market value of the Corresponding New Common Stock”